FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF SOLID LIPID NANOPARTICLES OF GEMCITABINE HYDROCHLORIDE

  • Shahanoor Momin Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
  • Shadab Khan Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
  • D M Ghadge Department of Pharmaceutics, Gourishankar institute of pharmaceutical Education and Research, Limb, Satara, (MS), India
  • K S Bhise Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India

Abstract

Gemcitabine Hydrochloride is a BCS class III drug of choice in the treatment of cancer, as a single or in combination chemotherapy. However, its bioavailability is a major concern due to its short half-life. Solid lipid nanoparticles (SLN) of Gemcitabine Hydrochloride were prepared to enhance its bioavailability, hence anticancer activity. The Quality by Design approach was applied for the formulation of SLN. The Randomized 32 factorial design was used with responses of particle size and % entrapment efficiency (% EE). The optimized batch of Gemcitabine Hydrochloride loaded SLN containing 1gm of GMS as solid lipid, 1gm of Tween80: Sodium Taurocholate as surfactant:co-surfactant and 5mg of Gemcitabine Hydrochloride was prepared by high shear homogenization method followed by Probe sonication for 15min to form nanoparticulate SLN dispersion. The Optimized batch of Gemcitabine Hydrochloride loaded SLN that exhausted mean particle size of 126.1nm, zeta potential -28.6 mV and % EE 74.83% respectively. SEM studies revealed three-dimensional nature of SLN with a slightly rough surface. DSC, results exhibited entrapment of Gemcitabine Hydrochloride in SLN. The optimized batch of SLN was evaluated for in-vitro % drug release using cellulose membrane dialysis bags for 24hrs and showed 63.13% CDR at 24 hrs. Anticancer cell line studies were also performed in human lung cancer cell line (A-549). It concludes that Gemcitabine Hydrochloride loaded Solid lipid Nanoparticles was successfully formulated and evaluated to sustain the drug release by bypassing the first pass metabolism.

Key words: Gemcitabine Hydrochloride, SLN, QbD, High shear homogenization, anticancer activity.

 

Downloads

Download data is not yet available.

Author Biographies

Shahanoor Momin, Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
Shadab Khan, Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
D M Ghadge, Department of Pharmaceutics, Gourishankar institute of pharmaceutical Education and Research, Limb, Satara, (MS), India
Department of Pharmaceutics, Gourishankar institute of pharmaceutical Education and Research, Limb, Satara, (MS), India
K S Bhise, Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India
Department of Pharmaceutics, M.C.E. Society’s Allana College of Pharmacy, Pune-411001, Maharashtra, India

References

1. Mitra S, Mitra AN. Nanoparticulate carriers in drug delivery and targeting. PINSA B68 No. 4, 2002; pp 349-360.
2. Abratt RP. Gemcitabine Hydrochloride: Combination of activity and tolerability. Anticancer Drugs, 1995; 6:63-64.
3. Manjunath K, Reddy JS, Venkateswarlu V., Solid lipid nanoparticles as drug delivery systems, Methods Find. Exp. Clin. Pharmacol. 2005; 27:127-144.
4. Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen A, Weyhers H, Freitas C, Rühl D, Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery, Eur. J. Pharm. 1995; 41:62-69.
5. Gohla S, Rainer H, MuÈller, Karsten MaÈder, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of art. Eur. J. Pharm. Biopharm. 2000; 50:161-177.
6. Lawrence TS. Radiation sensitizers and targeted therapies, oncology. 2003; 17:23-28.
7. Mokashi AS, Solid lipid nanoparticles of gemcitabine hydrochloride. bentham science publishers 2012; 2:0000-0000.
8. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm.(1996; 43:104-109.
9. Reddy LH. Couvreur, P.Novel Approaches to deliver gemticabine to cancers. Curr.Pharm. Des., 2008; 14:1124-1137.
10. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by design: Concepts for ANDAs, The AAPS Journal, 2008; 10:268–276.
11. Nadpara NP, Quality By Design (QBD): A complete Review. Int.J.pharm.sci.Rev.Res. 2012; 17(2):04, 20-28.
12. Skehn P, Storeng R, Scudiero A, Monks J, McMohan D, Vistica D, Jonathan TW, Bokesch H, Kenney S, Boyd M R. New colorimetric cytotoxicity assay for anticancer drug screening J. Natl. Cancer Inst. 1990; 82:1107.
13. Vichai V, Kanyawim K. Sulforhodamine B colorimetric assay for cytotoxicity screening Nature Protocols. 2006; 1:1112-1116.
Statistics
178 Views | 137 Downloads
How to Cite
Momin, S., Khan, S., Ghadge, D., & Bhise, K. (2017). FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF SOLID LIPID NANOPARTICLES OF GEMCITABINE HYDROCHLORIDE. Journal of Drug Delivery and Therapeutics, 7(1), 1-12. https://doi.org/10.22270/jddt.v7i1.1349